Latest news and insights on the pharmaceutical industry | Indian Pharma Post
Diagnostic Center
Diagnostic Center | 23 September 2023

Merck and Eisai update on Two Phase 3 Trials Evaluating Keytruda plus Lenima for cell lung cancer

The companies will work with investigators to share the results with the scientific community

Diagnostic Center
Diagnostic Center | 20 September 2023

BioNTech and CEPI partnership to advance mRNA Mpox Vaccine development

The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases

Diagnostic Center
Diagnostic Center | 19 September 2023

CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData

CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology

Diagnostic Center
Diagnostic Center | 11 September 2023

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran

Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension

Diagnostic Center
Diagnostic Center | 29 August 2023

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year

Diagnostic Center
Diagnostic Center | 28 August 2023

Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders

In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers

Diagnostic Center
Diagnostic Center | 25 August 2023

Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer

SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators

Diagnostic Center
Diagnostic Center | 16 August 2023

CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests

CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions

Diagnostic Center
Diagnostic Center | 21 July 2023

Merck’s Phase 3 Keynote- A18 trial met PFS in patients with advanced cervical cancer

KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients

Diagnostic Center
Diagnostic Center | 18 July 2023

PredOmix, Core Diagnostics partner to launch OncoVeryx-F

OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection

Diagnostic Center
Diagnostic Center | 29 June 2023

Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials

Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials

Diagnostic Center
Diagnostic Center | 10 June 2023

Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in NAFLD patients with comorbidities

The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52

Diagnostic Center
Diagnostic Center | 05 June 2023

Keytruda+ chemotherapy improves overall survival versus chemotherapy alone for unresectable advanced pleural mesothelioma

In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone

Diagnostic Center
Diagnostic Center | 02 June 2023

Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options

Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone

Diagnostic Center
Diagnostic Center | 20 May 2023

Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement

Diagnostic Center
Diagnostic Center | 09 May 2023

Briefs: Krsnaa Diagnostics

Krsnaa Diagnostics has commenced its fourth out of eight Diagnostics Center in Ayodhya

Diagnostic Center
Diagnostic Center | 02 May 2023

Lilly's Lebrikizumab shows improved face or hand dermatitis

Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients

Diagnostic Center
Diagnostic Center | 21 April 2023

Ashland diagnostic films medical device facilities achieve ISO certification

Gafchromic films support patient care in oncology

Diagnostic Center
Diagnostic Center | 18 April 2023

Ascentage presents results of studies underscoring exploratory efforts in potential

The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications

Diagnostic Center
Diagnostic Center | 17 April 2023

Molbio Diagnostics and SigTuple join hands to build next-gen diagnostic testing devices

The blood test market worldwide is today around $75-80 billion